冠状动脉慢血流治疗的研究进展

Recent progress of therapy in coronary slow flow phenomenon

冠状动脉慢血流现象(CSFP)是一种病因不明的冠状动脉疾病,临床表现类似冠状动脉粥样硬化性心脏病,冠状动脉造影未见明显狭窄,但却发生血流灌注延迟现象。目前对CSFP发生的机制尚存在争议,治疗上也同样无明确指南。临床上针对CSFP的药物主要有以下几类:他汀类、β受体阻滞剂、钙离子拮抗剂、双嘧达莫、曲美他嗪等。这几种药物虽然都有一定改善慢血流现象的作用,但都未在临床上大规模使用。尼可地尔作为近些年用于治疗CSFP的新药,其独特的扩张血管作用,可能成为治疗CSFP的新方向。

Coronary slow flow phenomenon （CSFP） is a coronary disease of unknown etiology and its clinical manifestations are similar to coronary atherosclerotic heart disease. The patients？ coronary angiographic findings indicate that coronary is characterized by delayed progression of contrast medium in an epicardial coronary artery without stenosis. There is no effective therapy to alter this phenomenon. The third generation p receptor blocker,calcium antagonist,dipyridamole, vasorel may be effective for treating CSFP,but they are not clinically used on a large scale. Nicorandil has been used in the treatment of CSFP in recent years. The vasodilator action of nicorandil makes it a new way of treating CSFP.